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Introduction: HAPLO-HSCT is a therapeutic option for pa-
tients with high-risk hematologic neoplasms with the ad-
vantages of quick availability, easy programation and
logistics, and a committed donor. It has shown promising
results in patients diagnosed with relapsed or refractory
Hodgkin’s lymphoma (HL) at least comparable to allogeneic
transplant from siblings or unrelated donors (Burroughs LM
et al. Biol Blood Marrow Transplant 2008; 14:1279-1287).
Patients and Methods: We retrospectively evaluate the re-
sults of HAPLO-HSCT with IV Busulfan (BUX) based RIC reg-
imens (Fludarabine 30 mg/m2 x5 days (-6 to -2),
Cyclophosphamide14,5mg/kg x2 days (-6 to -5), BUX 3,2mg/
kg x 1 (BUX1) or 2 days (BUX2) on days -3 to -2) and GVHD
prophylaxis based on PT-CY (50 mg/kg on days +3 and +4)
and a calcineurin inhibitor plus mycophenolate from day +5
performed in GETH centers to patients diagnosed with
relapsed or refractory HL.
Results: From March 2009, 43 HAPLO-HSCT have been per-
formed in patients diagnosed with relapsed or refractory HL
in 11 GETH centers. Median age was 31 years (17-53), 67%
were males and all were in advanced phases of their disease,
after a median of 4 prior treatment lines (2-8). Autologous
HSCT was previously employed in 79%, and allogeneic HSCT
in 7%. Five patients (11.5%) have received more than 2 prior
transplants. Disease status at HAPLO-HSCT evaluated by PET
was complete remission in 14 (32%) and persistent disease in
29 (68%). Bone marrow was employed in 11 (26%) and pe-
ripheral blood in 32 (74%), without T-cell depletion in all
cases. The haploidentical donor was patient’s mother (20),
father (3), siblings (19) or daughter (1). The RIC regimens
employed were BUX1 in 14 (32.5%) and BUX2 in 29 patients
(67.5%). Median neutrophils engraftment was day +18 (13-
44) and platelets >20K was day +26 (13-150). Graft failure
with autologous reconstitution happened only in 1 patient
(2.5%). The day +100 cumulative incidence (CI) of non-
relapse mortality (NRM) was 7% (3/43) and 16% (7/43) at 1
year post-transplant. The day +100 CI of grade II-IV acute
GVHD was 43%, and grade III-IV was 14.5%. Chronic GVHD CI
was 26.5% at 1 year, being extensive in 6%. After a median
follow-up for survivors of 13 months (3-60), the event-free
survival (EFS) was 59.5% and overall survival (OS) was 84%.
The 1-year CI of relapse or progression was 25%. Factors
related with better 1-year EFS were CR prior to HAPLO-HSCT
(93% vs 45%; p¼0.017) and receiving less than 4 treatment
lines prior to HAPLO-HSCT (100% vs 51.5%; p¼0.018). No
signiﬁcant differences were seen when comparing BUX1
against BUX2 in terms of NRM, EFS or OS.
Conclusions: HAPLO-HSCT with PT-CY and BUX based RIC
conditioning in relapsed or refractory HL patients, renders
long-lasting remissions with acceptable toxicity and GVHD,Figure. Overall survival and relapse risk according to probtaining better results in those transplanted in CR and with
less than 4 treatment lines prior to HAPLO-HSCT.82
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Background: Despite high curative rates with upfront ther-
apy, 20-30% of patients (pts) with Hodgkin lymphoma (HL)
experience disease relapse. Survival is further diminished for
those who fail autologous stem cell transplantation (ASCT).
However a fraction of pts can still be salvagedwith allogeneic
hematopoietic cell transplantation (allo-HCT).
Methods: In this retrospective cohort study, we investigated
the prognostic signiﬁcance of FDG-PET (interpreted by both
standard and Deauville criteria) among 42 consecutive pa-
tients with relapsed/refractory (RR) HL undergoing allo-HCT
from 2004-2012. All FDG-PET scans were obtained within 4
weeks prior to allo-HCT. The study cohort included recipients
of non-myeloablative (NMA) conditioning consisting of ﬂu-
darabine 150-200 mg/m2, cyclophosphamide 50 mg/kg and
total body irradiation TBI 200 cGy followed by trans-
plantation of umbilical cord blood (n¼30; 71%), matched
related (n¼10; 24%) and unrelated (n¼2; 5%) donor grafts.
Results: The median age was 28 years (range, 6-59); 52%
were males. Median time from HL diagnosis to allo-HCT was
34.6 months (range, 13.3-228.6) and median follow up of pts
was 26.5 months (range, 0.8-97.1). Pts had received a median
of 4 lines (range, 3-9) of prior regimens with 83% failing
ASCT; only 13 pts (31%) had achieved PET-negative (neg) CR
prior to allografting. Blinded re-evaluation of all pre-HCT
FDG-PET scans using Deauville 5-point scale (i.e. PETD-pos if
Deauville>3) by independent nuclear medicine physicians
conﬁrmed all pre-existing PET-neg reports, but also reclas-
siﬁed 4 prior PET-pos scans as PETD-neg (kappa coef-
ﬁcient¼0.79 [95% CI, 0.61-0.98] for PETD vs. archived PET). All
17 PETD-neg pts had signiﬁcantly better 3-yr post-transplant
OS, PFS, and relapse rate as compared to PETD-pos pts (100%
vs. 51%; 76% vs. 17%; 24% vs. 65%, respectively; all p<0.01,
Figure). Three out of four reclassiﬁed PETD-neg pts remained
alive and in remission after a median follow up of 3.3 yearse-transplant FDG-PET status by Deauville criteria.
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was 7% (0% for PETD-neg vs. 12% for PETD-pos, p¼0.1). Pre-
HCT PETD-neg status remained prognostic for improved 3-
yr OS (HR¼0.1; 95% CI, 0-0.86) and lower relapse risk
(HR¼0.34; 95% CI, 0.1-1.0) in the multivariable Cox models.
Conclusions: Our study demonstrates encouraging out-
comes achieved with NMA allo-HCT in heavily pre-treated
pts (3-yr OS, PFS and relapse of 72% [95% CI, 54%-84%], 40%
[95% CI, 24%-55%], 48% [95% CI, 29%-66%], respectively). FDG-
PET imaging interpreted by Deauville criteria can serve as a
powerful prognostic tool in pts with RR HL considered for
NMA allo-HCT.83
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Adult T-cell leukemia/lymphoma (ATLL), which is a human
T-lymphotropic virus type I (HTLV-1)-related hematological
malignancy, is known as a poorly prognostic disease even
with the intensive chemotherapeutic regimens. It is known
that ATLL cells normally have chromosomal abnormalities.
These abnormalities were various types of numerical aber-
rations and complex structural abnormalities (Kamada N et
al. Cancer Res. 1992). So far only one report showed that the
impact of chromosome abnormalities for survival outcomes
in ATLL patients who received chemotherapies (Itoyama T et
al. Blood 2001). The report suggested that complex karyo-
type (more than 6 break points) abnormalities of 1p, 1q, 3q,
14q, and 17q was the poorly prognostic factors. Herewe have
analyzed the impact of chromosomal abnormalities in 26
ATLL patients who received allo-HSCT.
Seventy-two ATLL patients consecutively underwent allo-
HSCT from June 2006 to March 2014 at our center. Karyotype
study was performed with G-banding stain. Since patients’
chromosomal study showed normal karyotype and/or bad
proliferation or no information about chromosomal study, 46
of 72 patients were excluded from this study. The rest of 26
patients (13 male, 13 female) were eligible for this study.
Themedian age of patients was 54 years (34-65). All patients,
except one lymphoma type patient, were diagnosed as acute
type ATLL. Thirteen of 26 patients were performed unrelated
BMT, 8 sibling-BMT, 2 sibling PBSCT and 3 UCB. Eighteen
patients used MAC regimens and 8 RIC regimens. With
respect to disease status at allo-HSCT, 6 patients were in CR,
and 20 non-CR. Specimen materials were from 11 PB, 8 BM,
6 lymph node and 1 pleural effusion, respectively. The
median number of numerally chromosomal abnormalities
was 2 (0-10), and the median number of structural abnor-
mality was 4 (0-12), respectively. The majorities of numeral
abnormalities were defects of sex chromosomes (31%), -14
(24%) and -10 (17%), etc. Structurally, more than 6 break
points of the chromosomal abnormalities were seen in 11
patients. Majorities of structural abnormalities were abnor-
malities of 14q (41%), 1q (28%), 4q (28%) and 7q (28%), etc.
The median study observation days was 173 days (12-2895)
and an overall survival (OS) was 40.7%. Statistically, no im-
pacts were seen in chromosomal abnormality of more than 6
break points (HR:1.839, 95%CI: 0.67-5.04, P¼0.237), abnor-
malities of 1q (HR: 2.035, 95%CI: 0.718-5.77, P¼0.182), 3q
(HR: 1.1, 95%CI: 0.312-3.88, P¼0.882), 14q (HR: 1.516, 95%CI:0.565-4.07, P¼0.409) and any other chromosomal abnor-
malities with OS. Also, no statistical impacts were seen in
these chromosomal abnormalities with relapse rate and non-
relapse mortality after allo-HSCT, respectively.
Although relatively a small number study, the results newly
showed that allo-HSCT would have a potential to overcome
the poor prognostic risks in chromosomal abnormalities.84
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Background: Two recent retrospective analyses suggested
that a combination of busulfan (Bu) andMel (Bu-Mel) may be
associated with a longer progression-free survival (PFS)
compared to Mel alone. In this randomized phase III trial we
compared the safety and efﬁcacy of Bu-Mel vs. Mel.
Methods: Patients were randomized to either Bu-Mel or Mel
using the Pocock-Simon method. In the Bu-Mel arm, Bu
130 mg/m2 was infused daily for 4 days, followed by 2 daily
doses of Mel at 70 mg/m2. Mel 200 mg/m2 was given as a
single dose in the Mel only arm. The primary endpoint was
Day 90 CR (IMWG criteria) rate.
Results: Ninety-two patients (Bu-Mel: 49, Mel: 43) were
enrolled from October 2011 to August 2013. Median ages at
auto-HCT were 58.4 and 58.5 years in Bu-Mel and Mel arms,
respectively (p¼0.75). Ten (20%) and 11 (26%) patients had
high-risk chromosomal abnormalities in Bu-Mel vs. Mel,
respectively (p¼0.62). Forty-four (90%) and 40 (93%) patients
received bortezomib-based induction therapy in the Bu-Mel
and Mel, respectively (p¼0.71). At the time of auto-HCT,
8/0 (16%) and 7/3 (23%) patients were in CR/near (n)CR in Bu-
Mel and Mel arms, respectively (p¼0.44), Grade 3 non-he-
matologic toxicity was seen in 41 (84%) and 20 (47%) patients
in Bu-Mel and Mel, respectively (p¼0.0003). There was no
100-day TRM in either arm. At day 90, 8 (16%) and 15 (35%)
patients had achieved a CR (p¼0.05), and 13 (27%) and 20
(47%) patients had achieved a CR + nCR (p¼0.05) in Bu-Mel
and Mel, respectively. At day 90, 7/7 (100%) evaluable pa-
tients with CR in Bu-Mel and 14/15 (93%) evaluable patients
with CR in Mel also achieved a multiparametric ﬂow cyto-
metric (MFC) CR (p¼1.00). Thirty-nine (80%) patients in
Bu-Mel and 37 (86%) in Mel received maintenance therapy
after day 90 (p¼0.58). Median follow up was 15.7 months
(range 0.8 e 28.7). No second primary malignancies have
been seen in either arm so far. Bayesian multivariable
lognormal survival time regression showed signiﬁcantly
better PFS in the Bu-Mel arm (posterior probability of the
treatment effect >0.9963, 95% credible interval 0.21-1.70,
Figure 1). Median PFS fromDay 90was not reached in the Bu-
Mel arm. Median PFS from Day 90 for Mel only was 20
months. One-year survival rates in the Bu-Mel vs Mel arms
were 91% (95% CI: 75-97%) and 77% (95% CI: 58-88%),
